Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease
Businesswire·2026-05-14 19:05

公司动态 - Ionis Pharmaceuticals的合作伙伴渤健公布了其靶向tau蛋白的在研反义寡核苷酸疗法diranersen在早期阿尔茨海默病患者中的2期CELIA研究的积极顶线结果 [1] - CELIA研究结果首次提供了来自随机2期试验的证据 表明一种靶向tau的疗法能对生物标志物产生显著影响 [1]

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease - Reportify